Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Sponsor: Replimune Inc.
ClinicalTrials ID:NCT04050436
This Phase 1/2 open-label study evaluates RP1, a replication-competent HSV-1, alone and with cemiplimab in advanced malignancies. Eligible patients have histologically confirmed advanced CSCC, measurable lesions, and ECOG ≤1. Interventions include intravenous cemiplimab and intratumoral RP1. Participants must provide tumor samples for pathology review.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.
Description
RP1 is a selectively replication competent herpes simplex virus type 1(HSV-1). This is a Phase 1/2, open-label, multicenter repeat-dosing study of RP1 alone and in combination with nivolumab in patients with advanced malignancies, and contains both single agent dose escalation, dose expansion to include nivolumab, and the combination in multiple Phase 2 cohorts in individual tumor types.
Eligibility Criteria
Inclusion Criteria
- Histologically confirmed locally advanced or metastatic cutaneous squamous cell carcinoma
- Patients with locally advanced disease who are not suitable candidates for surgical or radiological treatment of lesions or have refused those treatments
- At least 1 lesion that is measurable and injectable by study criteria
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1. Patients with ECOG PS 2 at baseline may be allowed to enroll if PS 2 status is only related to the CSCC disease under study
- Anticipated life expectancy >12 weeks
- All patients must consent to provide archived or newly obtained tumor material for central pathology review for confirmation of diagnosis of CSCC.
Key
Exclusion Criteria
- Prior treatment with an oncolytic therapy
- Patients with active significant herpetic infections or prior complications of HSV-1 infection (e.g. herpetic keratitis or encephalitis)
- Patients who require intermittent or chronic use of systemic (oral or intravenous) anti-virals with known anti-herpetic activity (e.g. acyclovir)
- Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments
- Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.
- Prior treatment with other immune modulating agents other than as adjuvant or neoadjuvant therapy within 3 years.
- Untreated brain metastasis(es) that may be considered active.
- Acute or chronic active hepatitis B or known history of hepatitis B or hepatitis C or human immunodeficiency virus (HIV) infection
- History of ILD/pneumonitis within the last 5 years or a history of ILD/pneumonitis requiring treatment with systemic steroids.
- Any major or surgical procedure ≤ 28 days before randomization
- Administration of live vaccines ≤ 28 days before randomization
Note: Other protocol defined Inclusion/Exclusion criteria apply.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of California San Diego | 92093 | La Jolla | California |
| University of California Los Angeles | 90024 | Los Angeles | California |
| Stanford University | 94305 | Stanford | California |
| University of Colorado Cancer Center | 80045 | Aurora | Colorado |
| University of Miami Health System | 33136 | Miami | Florida |
| Orlando Health UF Health Cancer Center | 32806 | Orlando | Florida |
| Moffitt McKinley Outpatient Center | 33612 | Tampa | Florida |
| Winship Cancer Institute of Emory University | 30322 | Atlanta | Georgia |
| John Theurer Cancer Center at Hackensack Univeristy Medical Center | 07601 | Hackensack | New Jersey |
| Memorial Sloan Kettering Cancer Center | 10065 | New York | New York |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.